Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 8, Pages 2314
Publisher
MDPI AG
Online
2020-08-17
DOI
10.3390/cancers12082314
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
- (2020) Xiaoxiang Zhou et al. BMC Medicine
- Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab
- (2019) Ichiro Yamauchi et al. PLoS One
- Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients
- (2019) Pauline Campredon et al. PRESSE MEDICALE
- Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review
- (2019) Jeroen M.k. de Filette et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study
- (2019) E. M. Presotto et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis
- (2019) Sahityasri Thapi et al. Journal for ImmunoTherapy of Cancer
- Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities
- (2019) Salahaldin A. Tahir et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?
- (2019) Bellesoeur et al. Cancers
- New insight in endocrine-related adverse events associated to immune checkpoint blockade
- (2019) Giusy Elia et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
- (2018) Koichi Sato et al. LUNG CANCER
- Association of Immune‐Related Adverse Events with Clinical Benefit in Patients with Advanced Non‐Small‐Cell Lung Cancer Treated with Nivolumab
- (2018) Yukihiro Toi et al. ONCOLOGIST
- Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab
- (2018) Kanako Sakurai et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
- (2018) Koji Haratani et al. JAMA Oncology
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- (2018) Romualdo Barroso-Sousa et al. JAMA Oncology
- Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National Pharmacovigilance database
- (2018) Julie Garon-Czmil et al. FUNDAMENTAL & CLINICAL PHARMACOLOGY
- Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma
- (2018) Yuka Mishima et al. INTERNAL MEDICINE
- Endocrine side effects of cancer immunotherapy
- (2017) Priscilla Cukier et al. ENDOCRINE-RELATED CANCER
- Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
- (2017) Ralf Gutzmer et al. EUROPEAN JOURNAL OF CANCER
- Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis
- (2017) Yan hong Shang et al. Immunotherapy
- A case of fulminant Type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible patient
- (2017) Manuel Araújo et al. Immunotherapy
- Isolated Adrenocorticotropic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer
- (2017) Kazuhiko Takaya et al. INTERNAL MEDICINE
- Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab
- (2017) Keiko Kitajima et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms
- (2017) Danae A Delivanis et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
- (2017) Shunsuke Teraoka et al. Journal of Thoracic Oncology
- Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies
- (2017) David J. Byun et al. Nature Reviews Endocrinology
- Immune‐Related Adverse Events as a Biomarker in Non‐Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors
- (2017) Julia Judd et al. ONCOLOGIST
- Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study
- (2017) Ichiro Yamauchi et al. THYROID
- Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution
- (2017) F. Guaraldi et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer
- (2017) James Luke Godwin et al. Journal for ImmunoTherapy of Cancer
- Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer
- (2016) J.C. Osorio et al. ANNALS OF ONCOLOGY
- PD-1/PD-L and autoimmunity: A growing relationship
- (2016) Mohammad Reza Zamani et al. CELLULAR IMMUNOLOGY
- Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review
- (2016) M.N Joshi et al. CLINICAL ENDOCRINOLOGY
- Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis
- (2016) Omar Abdel-Rahman et al. Future Oncology
- Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
- (2016) Jeroen de Filette et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2016) Scott Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Immune Checkpoint Inhibitors in Non‐Small Cell Lung Cancer
- (2016) Benjamin Herzberg et al. ONCOLOGIST
- Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
- (2016) J. Weber et al. Cancer Immunology Research
- Late-onset panhypopituitarism in a 72-year-old male patient treated with ipilimumab for metastatic melanoma: a case report
- (2016) G. Vancieri et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer
- (2016) Omar Hasan Ali et al. OncoImmunology
- Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
- (2016) Jared R. Lowe et al. Journal for ImmunoTherapy of Cancer
- Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report
- (2015) Juan Martin-Liberal et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
- (2015) M. Freeman-Keller et al. CLINICAL CANCER RESEARCH
- Toxicities of Immunotherapy for the Practitioner
- (2015) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab
- (2015) Tomohiko Narita et al. JOURNAL OF DERMATOLOGY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
- (2015) Alexander Faje Pituitary
- Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
- (2015) Krzysztof M. Zak et al. STRUCTURE
- Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
- (2015) Martina Sanlorenzo et al. JAMA Dermatology
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- (2014) Mabel Ryder et al. ENDOCRINE-RELATED CANCER
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
- (2013) P. A. Ott et al. CLINICAL CANCER RESEARCH
- Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
- (2013) Salvatore Maria Corsello et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of the PD-1 Pathway in the Immune Response
- (2012) L. V. Riella et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Reversible impairment of the processing of proopiomelanocortin into ACTH in pituitary enlargement suspected of lymphocytic hypophysitis
- (2012) Hiroshi Akahori ENDOCRINE JOURNAL
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- High Rate of Persistent Hypothyroidism in a Large-Scale Prospective Study of Postpartum Thyroiditis in Southern Italy
- (2010) Alex Stagnaro-Green et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started